Corinne Faivre-Finn
Led CONVERT, which set the radiotherapy schedule for limited-stage small-cell lung cancer.
Overview
Corinne Faivre-Finn was chief investigator of CONVERT, the international trial that compared twice-daily and once-daily thoracic radiotherapy in limited-stage SCLC and confirmed twice-daily 45 Gy as the standard. She co-leads studies of radiotherapy-immunotherapy combinations in the PACIFIC and ADRIATIC era and the Christie's thoracic radiotherapy research group.
| Title | Journal | Year |
|---|---|---|
| Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT) | Lancet Oncology | 2017 |
| Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC: an update from the PACIFIC trial | Journal of Thoracic Oncology | 2021 |
Pages like this
not linked directly; found by shared links- TermLimited-stage vs extensive-stage (SCLC)
Shares CONVERT, ADRIATIC, Small-cell lung cancer.
- PersonJeffrey D. Bradley
Shares IMRT / IGRT (modern external beam), Non-small-cell lung cancer and the tag radiotherapy.
- PersonValerie W. Rusch
Shares Journal of Thoracic Oncology, Non-small-cell lung cancer.
- PersonA. Murray Brunt
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
- PersonTimothy J. Whelan
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
- PersonAnthony V. D'Amico
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
- PersonBas W. Raaymakers
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.
- PersonCharlotte E. Coles
Shares IMRT / IGRT (modern external beam) and the tag radiotherapy.